Cardiomyopathy associated with the use of anabolic androgenic steroids. Case report
- Authors: Charaya K.V.1, Erdniev T.N.1, Makarenko G.D.1, Chashkina M.I.1, Gogiberidze N.A.1, Dumikyan A.S.1, Shchekochikhin D.Y.1, Chomakhidze P.S.1, Poltavskaya M.G.1, Andreev D.A.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 26, No 10 (2024): CARDIOLOGY AND NEPHROLOGY
- Pages: 661-665
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/271602
- DOI: https://doi.org/10.26442/20751753.2024.10.202890
- ID: 271602
Cite item
Full Text
Abstract
The use of anabolic androgenic steroids (AAS) in supraphysiologic doses is associated with a number of adverse effects on the cardiovascular system. In the presented clinical case, a bodybuilder athlete abusing AAS developed heart failure with a decrease in left ventricular ejection fraction of up to 20%. The peculiarity of the case is the recovery of left ventricular ejection fraction under the influence of drug therapy and withdrawal from AAS use with subsequent decrease after resumption of drug intake. In this case, we observed two types of myocardial damage – both ischemic and non-ischemic.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Kristina V. Charaya
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: charaya9716@gmail.com
ORCID iD: 0000-0002-7071-5752
Аssistant
Russian Federation, MoscowTamerlan N. Erdniev
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0003-4253-1646
Student
Russian Federation, MoscowGalina D. Makarenko
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0009-0003-4567-4076
Resident
Russian Federation, MoscowMaria I. Chashkina
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0002-9593-6148
Cand. Sci. (Med.)
Russian Federation, MoscowNana A. Gogiberidze
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
Аssistant
Russian Federation, MoscowAnait Sh. Dumikyan
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0002-7580-3401
Cand. Sci. (Med.)
Russian Federation, MoscowDmitry Yu. Shchekochikhin
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0002-8209-2791
Cand. Sci. (Med.)
Russian Federation, MoscowPetr Sh. Chomakhidze
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0003-1485-6072
D. Sci. (Med.)
Russian Federation, MoscowMaria G. Poltavskaya
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0003-4463-2897
D. Sci. (Med.)
Russian Federation, MoscowDenis A. Andreev
Sechenov First Moscow State Medical University (Sechenov University)
Email: charaya9716@gmail.com
ORCID iD: 0000-0002-0276-7374
D. Sci. (Med.)
Russian Federation, MoscowReferences
- Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383-98. doi: 10.1016/j.annepidem.2014.01.009
- Fadah K, Gopi G, Lingireddy A, et al. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023;10:1214374. doi: 10.3389/fcvm.2023.1214374
- Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Front Endocrinol (Lausanne). 2022;13:1059473. doi: 10.3389/fendo.2022.1059473
- Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644-51. doi: 10.1249/01.mss.0000210194.56834.5d
- Лихоносов Н.П., Бабенко А.Ю. Медицинский аспект использования анаболических андрогенных стероидов у мужчин, посещающих тренажерные залы Санкт-Петербурга. Проблемы эндокринологии. 2019;65(1):Art. no. 1. doi: 10.14341/probl9832
- Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901. doi: 10.1016/j.amjcard.2010.05.013
- Sader MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001;37(1):224-30. doi: 10.1016/s0735-1097(00)01083-4
- Dickerman RD, Schaller F, Zachariah NY, McConathy WJ. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med. 1997;7(2):90-3. doi: 10.1097/00042752-199704000-00003
- Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction. Echocardiography Results of the HAARLEM Study. Front Reprod Health. 2021;3:732318. doi: 10.3389/frph.2021.732318
- Bergink EW, Geelen JA, Turpijn EW. Metabolism and receptor binding of nandrolone and testosterone under in vitro and in vivo conditions. Acta Endocrinol Suppl (Copenh). 1985;271:31-7. doi: 10.1530/acta.0.109s0031
- Sharma S. Athlete’s heart – effect of age, sex, ethnicity and sporting discipline. Exp Physiol. 2003;88(5):665-9. doi: 10.1113/eph8802624
- Nottin S, NguyenL-D, Terbah M, Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol. 2006;97(6):912-5. doi: 10.1016/j.amjcard.2005.10.026
- Krieg A, Scharhag J, Albers T, et al. Cardiac tissue Doppler in steroid users. Int J Sports Med. 2007;28(8):638-43. doi: 10.1055/s-2007-964848
- Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135(21):1991-2002. doi: 10.1161/CIRCULATIONAHA.116.026945
- Luijkx T, Velthuis BK, Backx FJ, et al. Anabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. Int J Cardiol. 2013;167(3):664-8. doi: 10.1016/j.ijcard.2012.03.072
- Søndergaard EB, Thune JJ, Gustafsson F. Characteristics and outcome of patients with heart failure due to anabolic-androgenic steroids. Scand Cardiovasc J. 2014;48(6):339-42. doi: 10.3109/14017431.2014.976837
- Santora LJ, Marin J, Vangrow J, et al. Coronary calcification in body builders using anabolic steroids. Prev Cardiol. 2006;9(4):198-201. doi: 10.1111/j.1559-4564.2006.05210.x
- Montisci M, El Mazloum R, Cecchetto G, et al. Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci Int. 2012;217(1-3):e13-8. doi: 10.1016/j.forsciint.2011.10.032 d
- Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2007;121(1):48-53. doi: 10.1007/s00414-005-0055-9
- López B, González A, Ravassa S, et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. J Am Coll Cardiol. 2015;65(22):2449-56. doi: 10.1016/j.jacc.2015.04.026
Supplementary files
